These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38031681)

  • 1. Use of Janus kinase inhibitors in atopic dermatitis - an update.
    Dhar S; Datta S; De A
    Indian J Dermatol Venereol Leprol; 2023 Oct; ():1-8. PubMed ID: 38031681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase inhibitors for the therapy of atopic dermatitis.
    Traidl S; Freimooser S; Werfel T
    Allergol Select; 2021; 5():293-304. PubMed ID: 34532638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
    Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
    Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H; Jia H; Xia T; Zhang D
    Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
    Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
    J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
    Nakashima C; Yanagihara S; Otsuka A
    Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis.
    Perche PO; Cook MK; Feldman SR
    Ann Pharmacother; 2023 Jan; 57(1):86-98. PubMed ID: 35587593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib.
    Nogueira M; Torres T
    Dermatol Pract Concept; 2021 Oct; 11(4):e2021145. PubMed ID: 35024237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
    Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
    Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
    Narla S; Silverberg JI
    Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
    Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
    Drugs Context; 2020; 9():. PubMed ID: 33240390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
    Sun C; Su Z; Zeng YP
    Inflamm Res; 2023 Sep; 72(9):1861-1871. PubMed ID: 37707560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
    Alves C; Penedones A; Mendes D; Batel Marques F
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents.
    Nusbaum KB; Nguyen CM; Fleischer AB
    J Dermatolog Treat; 2022 May; 33(3):1274-1278. PubMed ID: 33143506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
    Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
    Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Janus kinase inhibitors for the treatment of atopic dermatitis-evaluation of current data and practical experience].
    Lauffer F; Biedermann T
    Dermatologie (Heidelb); 2022 Jul; 73(7):520-528. PubMed ID: 35608635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
    Ferreira S; Guttman-Yassky E; Torres T
    Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
    Huang IH; Chung WH; Wu PC; Chen CB
    Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.